Walvax Biotechnology Future Growth
Future criteria checks 3/6
Walvax Biotechnology is forecast to grow earnings and revenue by 54.6% and 11.7% per annum respectively. EPS is expected to grow by 54.4% per annum. Return on equity is forecast to be 6.1% in 3 years.
Key information
54.6%
Earnings growth rate
54.4%
EPS growth rate
| Biotechs earnings growth | 43.2% |
| Revenue growth rate | 11.7% |
| Future return on equity | 6.1% |
| Analyst coverage | Low |
| Last updated | 29 Oct 2024 |
Recent future growth updates
Recent updates
Some Confidence Is Lacking In Walvax Biotechnology Co., Ltd.'s (SZSE:300142) P/S
Sep 24
Is Walvax Biotechnology (SZSE:300142) A Risky Investment?
Jun 19Walvax Biotechnology Co., Ltd.'s (SZSE:300142) Prospects Need A Boost To Lift Shares
May 23There May Be Reason For Hope In Walvax Biotechnology's (SZSE:300142) Disappointing Earnings
Apr 07Walvax Biotechnology Co., Ltd. (SZSE:300142) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Apr 02Is Walvax Biotechnology (SZSE:300142) A Risky Investment?
Mar 01Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2026 | 3,961 | 788 | N/A | 851 | 2 |
| 12/31/2025 | 3,605 | 646 | N/A | 1,006 | 2 |
| 12/31/2024 | 3,114 | 399 | N/A | 1,178 | 2 |
| 9/30/2024 | 3,097 | 122 | 163 | 832 | N/A |
| 6/30/2024 | 3,379 | 135 | 52 | 839 | N/A |
| 3/31/2024 | 3,880 | 262 | 5 | 855 | N/A |
| 12/31/2023 | 4,114 | 419 | 188 | 1,134 | N/A |
| 9/30/2023 | 4,538 | 751 | 214 | 1,191 | N/A |
| 6/30/2023 | 4,906 | 763 | 158 | 1,185 | N/A |
| 3/31/2023 | 5,264 | 862 | 218 | 1,395 | N/A |
| 1/1/2023 | 5,086 | 729 | 110 | 1,201 | N/A |
| 9/30/2022 | 5,040 | 595 | 160 | 1,311 | N/A |
| 6/30/2022 | 4,461 | 530 | -84 | 1,118 | N/A |
| 3/31/2022 | 3,685 | 434 | -263 | 856 | N/A |
| 1/1/2022 | 3,463 | 428 | -398 | 705 | N/A |
| 9/30/2021 | 3,501 | 932 | -660 | 267 | N/A |
| 6/30/2021 | 3,715 | 1,261 | -525 | 139 | N/A |
| 3/31/2021 | 3,260 | 1,053 | -452 | 26 | N/A |
| 12/31/2020 | 2,939 | 1,003 | -293 | 114 | N/A |
| 9/30/2020 | 1,890 | 457 | -275 | 120 | N/A |
| 6/30/2020 | 1,194 | 119 | -303 | 84 | N/A |
| 3/31/2020 | 1,057 | 85 | -343 | 13 | N/A |
| 12/31/2019 | 1,121 | 142 | -290 | 62 | N/A |
| 9/30/2019 | 1,098 | 1,444 | -241 | 72 | N/A |
| 6/30/2019 | 1,000 | 1,426 | -327 | -44 | N/A |
| 3/31/2019 | 933 | 1,430 | -265 | -13 | N/A |
| 12/31/2018 | 874 | 1,415 | -293 | -65 | N/A |
| 9/30/2018 | 807 | -407 | -307 | -81 | N/A |
| 6/30/2018 | 786 | -421 | N/A | -62 | N/A |
| 3/31/2018 | 700 | -484 | N/A | -14 | N/A |
| 12/31/2017 | 668 | -537 | N/A | -10 | N/A |
| 9/30/2017 | 628 | 265 | N/A | 70 | N/A |
| 6/30/2017 | 555 | 189 | N/A | 55 | N/A |
| 3/31/2017 | 466 | 83 | N/A | -33 | N/A |
| 12/31/2016 | 591 | 70 | N/A | -90 | N/A |
| 9/30/2016 | 692 | -963 | N/A | -153 | N/A |
| 6/30/2016 | 885 | -936 | N/A | -169 | N/A |
| 3/31/2016 | 1,045 | -835 | N/A | -133 | N/A |
| 12/31/2015 | 1,006 | -841 | N/A | -69 | N/A |
| 9/30/2015 | 843 | 182 | N/A | -44 | N/A |
| 6/30/2015 | 731 | 138 | N/A | -73 | N/A |
| 3/31/2015 | 705 | 147 | N/A | -16 | N/A |
| 12/31/2014 | 719 | 143 | N/A | -66 | N/A |
| 9/30/2014 | 816 | -139 | N/A | -149 | N/A |
| 6/30/2014 | 750 | -91 | N/A | -159 | N/A |
| 3/31/2014 | 676 | -29 | N/A | -149 | N/A |
| 12/31/2013 | 583 | 48 | N/A | -122 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 300142's forecast earnings growth (54.6% per year) is above the savings rate (2.8%).
Earnings vs Market: 300142's earnings (54.6% per year) are forecast to grow faster than the CN market (26.1% per year).
High Growth Earnings: 300142's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 300142's revenue (11.7% per year) is forecast to grow slower than the CN market (13.9% per year).
High Growth Revenue: 300142's revenue (11.7% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 300142's Return on Equity is forecast to be low in 3 years time (6.1%).